Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte

Three-year disease-free survival is an adequate endpoint for standard approval of a colorectal cancer agent in the adjuvant setting, FDA's Oncologic Drugs Advisory Committee concluded May 4